{"url_path":"/sec/hlyk/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1680139/0001213900-26-057581-index.html","accession_number":"0001213900-26-057581","cik":"0001680139","ticker":"HLYK","issuer_name":"HealthLynked Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1680139/0001213900-26-057581-index.html","primary_entity_key":"0001680139","primary_entity_name":"HealthLynked Corp"},"word_count":59,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n \n\nDuring the quarter ended March\n31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, or the\nExchange Act) adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as\nsuch terms are defined under Item 408 of Regulation S-K)."}